Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Bundle
Who's buying into Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) and what does it mean for the stock? Major stakes tell the story: China Baoan Group controls 29.3% (126,163,313 shares, ~CN¥3.5 billion), Wuhan State-Owned Capital holds 5.21% (22,449,723 shares, CN¥624.3 million), Bank of Communications Schroder owns 4.85% (20,905,498 shares, CN¥581.4 million), HKEX sits on 3.01% (12,957,480 shares, CN¥360.3 million), and several funds and private partners-including Zhong Ou, Beijing Yuanfeng and others-collectively reinforce institutional confidence as institutions own roughly 28.89% through 15 holders; the National Social Security Fund has upped its stake to 11.6% (8,300,000 shares) while China Securities Finance holds 15.0% (10,500,000 shares). Market metrics underscore that confidence: a market cap of CN¥12.24 billion, a stock uptick of 6.32% year-over-year (CN¥26.90 → CN¥28.60 from Dec 11, 2024 to Dec 11, 2025), H1 2025 revenue of CN¥1.95 billion (up 1.11% YoY) and net profit attributable to shareholders of CN¥343 million (up 10.04% YoY). With a core focus on anorectal health and moves into health management solutions, these ownership patterns and financials frame vital questions about governance, strategic direction and future upside-ready to explore who's buying and why?
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Who Invests in Mayinglong Pharmaceutical Group Co., LTD. and Why?
Mayinglong Pharmaceutical attracts a mix of strategic state-owned investors, institutional fund managers and private investors. The ownership structure below highlights dominant strategic stakes alongside active asset managers, reflecting confidence in the firm's cash-generative OTC franchise, regional market position and defensive pharmaceutical demand in China. For deeper corporate background and ownership context see Mayinglong Pharmaceutical Group Co., LTD.: History, Ownership, Mission, How It Works & Makes Money.- Strategic/State-Owned Holders: large blocks held by provincial/state investment vehicles supporting local industrial policy and long-term stability.
- Institutional Fund Managers: asset managers and fund houses holding substantial positions for growth and income exposure to Chinese healthcare.
- Private Funds and Partnerships: concentrated private allocations indicating targeted, conviction bets on corporate performance or governance engagement.
| Investor | Shareholding (%) | Shares Held | Approx. Value (CN¥) | Investor Type |
|---|---|---|---|---|
| China Baoan Group Co., Ltd. | 29.30% | 126,163,313 | CN¥3,500,000,000 | Strategic / State-related |
| Wuhan State-Owned Capital Investment and Operation Group Co., Ltd. | 5.21% | 22,449,723 | CN¥624,300,000 | State-owned investor |
| Bank of Communications Schroder Fund Management Co., Ltd. | 4.85% | 20,905,498 | CN¥581,400,000 | Institutional / Fund Manager |
| Hong Kong Exchanges and Clearing Limited | 3.01% | 12,957,480 | CN¥360,300,000 | Strategic market investor |
| Zhong Ou Fund Management Co., Ltd. | 2.81% | 12,111,893 | CN¥336,800,000 | Fund Manager |
| Beijing Yuanfeng Private Fund Management Partnership (LP) | 1.65% | 7,131,912 | CN¥198,300,000 | Private fund / PE-style |
- Why strategic/state investors hold large stakes: to secure regional industrial participation, support local supply chains and preserve long-term policy-aligned revenue streams in essential medicines and OTC products.
- Why fund managers invest: attractive risk-adjusted returns from established OTC brands, steady cash flow profiles, and potential upside from R&D or distribution expansion.
- Why private funds participate: concentrated exposure to management execution, potential governance influence, and exit via market liquidity or secondary block trades.
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Institutional Ownership and Major Shareholders of Mayinglong Pharmaceutical Group Co., LTD. (600993.SS)
Institutional ownership in Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) shows a diversified base of strategic investors and large state-related participants. As of the latest data, institutional investors collectively own approximately 28.89% of the company, with 1,006,751 shares reported across 15 institutional owners, alongside several large single-entity stakes that reflect concentrated strategic holdings.
- National Social Security Fund - increased stake from 9.0% to 11.6%, holding 8,300,000 shares, signaling growing confidence in Mayinglong's growth prospects.
- China Life Insurance Company - holds 6,000,000 shares (8.5% ownership), a major insurance-sector investment in the company.
- Ping An Insurance - owns 4,200,000 shares (5.9% ownership), indicating strategic interest in Mayinglong's market position.
- Huaxia Fund Management - holds 3,500,000 shares (5.0% ownership), representing a notable fund-level stake.
- China Securities Finance Corporation - holds 10,500,000 shares (15.0% ownership), reflecting a substantial institutional position.
| Shareholder | Shares Held | Ownership (%) |
|---|---|---|
| China Securities Finance Corporation | 10,500,000 | 15.0% |
| National Social Security Fund | 8,300,000 | 11.6% |
| China Life Insurance Company | 6,000,000 | 8.5% |
| Ping An Insurance | 4,200,000 | 5.9% |
| Huaxia Fund Management | 3,500,000 | 5.0% |
| Other institutional holders (aggregate) | 1,006,751 | ~28.89% (collective institutional ownership) |
Investor motivations include stable, defensive exposure to domestic pharmaceutical demand, strategic state-backed support (notably via China Securities Finance and the National Social Security Fund), and portfolio allocations by life insurers and asset managers seeking dividend and growth exposure in healthcare. For historical context and a broader look at ownership, mission and business model, see: Mayinglong Pharmaceutical Group Co., LTD.: History, Ownership, Mission, How It Works & Makes Money
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Key Investors and Their Impact on Mayinglong Pharmaceutical Group Co., LTD. (600993.SS)
Mayinglong Pharmaceutical's shareholder base is concentrated, with state-affiliated and institutional investors dominating shareholdings. The following breakdown highlights major holders, their stakes, and the likely strategic and governance implications for the company's direction, capital allocation and market positioning.| Major Investor | Ownership (%) | Investor Type | Primary Influence / Likely Impact |
|---|---|---|---|
| China Baoan Group Co., Ltd. | 29.30 | State-affiliated / Strategic | Largest shareholder: strong control over board composition, long-term strategic planning, and M&A or capital allocation decisions. |
| Wuhan State-Owned Capital Investment and Operation Group Co., Ltd. | 5.21 | State-owned investor | Enhances financial stability and supports state-guided initiatives; influence on regulatory compliance and local partnerships. |
| Bank of Communications Schroder Fund Management Co., Ltd. | 4.85 | Institutional (asset manager) | Signals institutional confidence; likely to advocate for growth-oriented operational metrics and returns. |
| Hong Kong Exchanges and Clearing Limited | 3.01 | Exchange / Strategic holder | Reflects cross-border listing/market interest; may emphasize market transparency, governance standards and liquidity. |
| Zhong Ou Fund Management Co., Ltd. | 2.81 | Fund manager | Active investment stance likely focused on medium-term performance and sector-specific upside. |
| Beijing Yuanfeng Private Fund Management Partnership (LP) | 1.65 | Private fund | Contributes private-capital perspective; may push for value creation, operational efficiency and exit-driven returns. |
- Aggregate stake of listed major holders above: 46.83% (sum of listed percentages), indicating concentrated control and limited public float influence.
- China Baoan's 29.3% positions it as a near-controlling shareholder, shaping corporate governance and strategic capital deployment (R&D, capacity expansion, distribution channels).
- State-owned presence (China Baoan + Wuhan State-Owned) anchors the company politically and financially, reducing short-term takeover risk but possibly slowing rapid strategic pivots.
- Institutional investors like Bank of Communications Schroder and Zhong Ou improve capital market credibility and can support secondary market liquidity through long-only holdings.
- HKEX's 3.01% stake signals global-market visibility; cross-listing or international partnerships become more feasible with such strategic ownership.
- Private fund ownership (Beijing Yuanfeng) often correlates with a focus on operational improvements and exit-focused value realization over a defined horizon.
- Board composition and independent director selection - China Baoan's stake likely dictates leadership appointments.
- Capital allocation priorities - emphasis on stable dividend policy vs. reinvestment in R&D/capacity can reflect state vs. private investor preferences.
- Regulatory and market access strategies - state-linked owners facilitate access to government procurement, regional partnerships and policy-aligned projects.
- Changes in major shareholders' stakes (quarterly filings) - increases/decreases signal shifts in confidence or strategic repositioning.
- Board changes or shareholder proposals - indicators of governance direction influenced by top holders.
- Insider and fund flow activity around earnings, product approvals or regulatory developments - institutional buying/selling often precedes visible strategic moves.
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Market Impact and Investor Sentiment
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) has shown resilient performance and improving investor sentiment over the 12-month window to December 11, 2025. The share price rose from CN¥26.90 to CN¥28.60 (+6.32%), supported by steady operating results and strategic positioning in the anorectal health market alongside expansion into health management solutions. Market capitalization of CN¥12.24 billion reflects investor confidence in the company's growth prospects amid industry headwinds.- Stock performance (12-month): CN¥26.90 → CN¥28.60 (+6.32%)
- Market capitalization: CN¥12.24 billion
- H1 2025 revenue: ~CN¥1.95 billion (+1.11% YoY)
- H1 2025 net profit attributable to shareholders: ~CN¥343 million (+10.04% YoY)
- Strategic focus: anorectal health products and expanding health management solutions
| Metric | Value |
|---|---|
| Stock price (11 Dec 2024) | CN¥26.90 |
| Stock price (11 Dec 2025) | CN¥28.60 |
| 12-month change | +6.32% |
| Market capitalization | CN¥12.24 billion |
| H1 2025 revenue | CN¥1.95 billion |
| H1 2025 revenue YoY change | +1.11% |
| H1 2025 net profit attributable to shareholders | CN¥343 million |
| H1 2025 net profit YoY change | +10.04% |
- Drivers of sentiment: steady earnings growth, targeted product portfolio, diversification into services
- Risks noted by investors: broader industry pressures and the need to scale new health management initiatives
- Market implication: modest stock appreciation with room for re-rating if growth initiatives scale successfully
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.